[Radiation therapy in head and neck cancer. Highlights from ASCO 2010].
Standard
[Radiation therapy in head and neck cancer. Highlights from ASCO 2010]. / Tribius, Silke; Petersen, Cordula; Knecht, Rainald; Ihloff, Anna-Sophie.
In: HNO, Vol. 58, No. 12, 12, 2010, p. 1168-1173.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [Radiation therapy in head and neck cancer. Highlights from ASCO 2010].
AU - Tribius, Silke
AU - Petersen, Cordula
AU - Knecht, Rainald
AU - Ihloff, Anna-Sophie
PY - 2010
Y1 - 2010
N2 - In contrast to conventional radiotherapy, intensity modulated radiotherapy (IMRT) enables individually adjusted dose and intensity depending on tumor size and organs at risk, thus enabling radiotherapy of complex volumes in the head and neck area using high doses. Despite new data presented at the annual congress of the American Society of Clinical Oncology (ASCO), questions remain unanswered in two basic categories: (a) How do we use IMRT with other important advances in head and neck cancer treatment, such as altered fractionation, chemotherapy, and novel agents? (b) Does IMRT in its current form produce sufficient risk:benefit improvements in salivary gland sparing/less xerostomia, better targeting/local control and less late toxicity? Whether IMRT with its complex target volume definition and dose distribution leads to improved local control needs to be further investigated in relevant studies.
AB - In contrast to conventional radiotherapy, intensity modulated radiotherapy (IMRT) enables individually adjusted dose and intensity depending on tumor size and organs at risk, thus enabling radiotherapy of complex volumes in the head and neck area using high doses. Despite new data presented at the annual congress of the American Society of Clinical Oncology (ASCO), questions remain unanswered in two basic categories: (a) How do we use IMRT with other important advances in head and neck cancer treatment, such as altered fractionation, chemotherapy, and novel agents? (b) Does IMRT in its current form produce sufficient risk:benefit improvements in salivary gland sparing/less xerostomia, better targeting/local control and less late toxicity? Whether IMRT with its complex target volume definition and dose distribution leads to improved local control needs to be further investigated in relevant studies.
M3 - SCORING: Zeitschriftenaufsatz
VL - 58
SP - 1168
EP - 1173
JO - HNO
JF - HNO
SN - 0017-6192
IS - 12
M1 - 12
ER -
